RT Journal Article
SR Electronic
T1 SARS-CoV-2 Spike Protein Receptor Binding-ACE2 Interaction Increases Carbohydrate Sulfotransferases and Reduces N-Acetylgalactosamine-4-Sulfatase through Phospho-p38-MAPK and RB-E2F1
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.24.23284890
DO 10.1101/2023.01.24.23284890
A1 Bhattacharyya, Sumit
A1 Tobacman, Joanne K.
YR 2023
UL http://medrxiv.org/content/early/2023/06/14/2023.01.24.23284890.abstract
AB Immunohistochemistry of post-mortem lung tissue from patients with SARS-CoV2 infection showed marked decline in intensity and distribution of N-acetylgalactosamine-4-sulfatase (Arylsulfatase B; ARSB), increase of total chondroitin sulfate by immunohistochemistry, and increase of vascular-associated carbohydrate sulfotransferase (CHST)15 [1]. The mechanisms leading to these observations were not explained by signaling pathways known to be activated by exposure to coronaviruses. This report addresses the underlying reactions leading to these observations in a cell-based model, using normal, human, primary small airway epithelial cells, treated with the SARS-CoV-2 spike protein receptor binding domain protein.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tissue collection was approved by the Ethics Committee of Northern and Central Switzerland (study ID 2020-00969).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.